BrainWaveBank
Cumulus Neuroscience operates the NeuLogiq Platform, a multi-modal digital and neurophysiological assessment system for in-clinic and at-home brain function monitoring in CNS clinical trials, serving top global pharmaceutical sponsors including a Top 10 Pharma Advisory Group.
- Company typePrivate
- Founded2015
- HeadquartersBelfast, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What BrainWaveBank does
Cumulus Neuroscience Limited, headquartered in Belfast with a second office in Dublin, operates the NeuLogiq® Platform, a multi-modal digital assessment and neurophysiological monitoring system designed for use in central nervous system (CNS) clinical trials. The platform combines digitized cognitive assessments with brain function data capture to enable frequent, longitudinal monitoring of patients both in clinic and at home, addressing well-documented pain points in CNS drug development such as placebo response, symptom heterogeneity, subjective endpoints, and the absence of objective biomarkers. It was co-designed with a Top 10 Pharma Advisory Group comprising Biogen, Boehringer Ingelheim, BMS, GSK, J&J, Lilly, MSD, Pfizer, Roche, and Takeda, lending clinical and commercial credibility from inception.
The company generates revenue through enterprise clinical trial services, providing platform access, data collection, and study support to pharmaceutical sponsors on what the source describes as a subscription or recurring engagement basis. Pricing is not publicly disclosed and is contact-based, consistent with bespoke enterprise contracts. The go-to-market motion is direct enterprise field sales — the company runs a 'Book a Demo' CTA and attends conferences such as AAIC — targeting translational and clinical operations buyers inside top-tier pharma. Funding has totaled approximately $16.4 million across nine equity and grant tranches from 2016 through 2020, sourced from a mix of regional venture funds (Par Equity, Clarendon, Whiterock, TechStart Ventures, ACF Investors, KX), UK life sciences investors (LifeArc), government programs (Innovate UK, Invest Northern Ireland), and the UK Future Fund. The current operating status is active, but post-2020 momentum cannot be confirmed from the available data.
Leadership comprises founder-CEO Ronan Cunningham, founder and CSO Brian Murphy, chairman Des Speed, and Professor Ian Robertson (Trinity College Dublin) as chair of the science advisory board, signaling deep neuroscience and academic ties.
BrainWaveBank firmographics
Firmographics- Name
- BrainWaveBank
- Legal name
- Cumulus Neuroscience Limited
- Website
- https://brainwavebank.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Cumulus Neuroscience operates the NeuLogiq Platform, a multi-modal digital and neurophysiological assessment system for in-clinic and at-home brain function monitoring in CNS clinical trials, serving top global pharmaceutical sponsors including a Top 10 Pharma Advisory Group.
- Ownership category
- akta.pro rank
BrainWaveBank industry classification
Industry- Product category
- Digital CNS Clinical Trial Technology
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Electronic Data Capture (EDC) Platforms (HLACAOAA)
- akta.pro secondary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where BrainWaveBank is headquartered
LocationHeadquarters
- HQ city
- Belfast
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
BrainWaveBank business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Trial Services: Revenue generated through providing the NeuLogiq Platform for use in CNS clinical studies conducted by pharmaceutical companies. Services likely include platform access, data collection, and support for clinical trials.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
BrainWaveBank product offering
Product offeringCore offering
BrainWaveBank develops digital tools that measure and track brain activity and cognitive performance for anyone, anytime, anywhere. The company provides multi-modal digital brain assessments combining neurophysiological data capture (including EEG) with digitized cognitive tests, enabling frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions. The technology underpins the NeuLogiq® Platform, designed in collaboration with 10 top pharmaceutical companies for use in central nervous system (CNS) clinical studies and drug development.
Product overview
Cumulus Neuroscience offers a unified platform called NeuLogiq® Platform. The platform provides multi-modal assessments for use in-clinic or at home, combining digital assessments and neurophysiological data to support CNS (Central Nervous System) drug development. The NeuLogiq Platform was designed for use in CNS clinical studies in collaboration with 10 Top Pharma Companies and includes features for frequent, reliable longitudinal monitoring of discrete brain functions.
Differentiator
Problem solved
Functional benefit
Brands
- NeuLogiq® Platform: A platform providing frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions, designed for use in CNS clinical studies.
Products and services
- NeuLogiq® Platform
Quantifiable outcome
- Achieve more data per participant, enabling powering of smaller studies
- +1 more outcomes
Companies that use BrainWaveBank
Customer profileNamed customers10 records
Segments1 record
Ideal customer profiles1 record
BrainWaveBank technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
BrainWaveBank partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core.
- BiogencoreTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group that helped design the platform for clinical relevance.
- Boehringer IngelheimcoreTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
- Bristol Myers Squibb (BMS)coreTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
- GSKcoreTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
- Johnson & Johnson (J&J)coreTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
- Eli LillycoreTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
- MSDcoreTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
- PfizercoreTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
- RochecoreTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
- TakedacoreTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
BrainWaveBank competitors and assessment
Company assessmentDirect peers
- Cambridge Cognition: Provides digital cognitive assessment tools (CANTAB) for CNS clinical trials — directly comparable to Cumulus's digitized cognitive assessment capability and the same pharma customer base.
- Cogstate: Specializes in computerized cognitive testing for clinical trials in CNS indications such as Alzheimer's, depression, and oncology — overlapping use case and customer profile to Cumulus.
- VivoSense: Wearable biosensor and continuous-monitoring platform specifically designed for clinical trials, including CNS indications — directly comparable remote-patient-monitoring value proposition to NeuLogiq.
- IXICO: UK-listed neuroimaging biomarker CRO serving CNS clinical trials in Alzheimer's, Huntington's, and other neurological indications — overlapping customer base and trial-endpoint focus.
- ActiGraph: Wearable activity, sleep, and digital endpoint monitoring platform used in CNS and other clinical trials — overlapping remote/at-home objective measurement capability in the same pharma trials.
Broad incumbents
- Clario: Large clinical trial technology provider (formed from ERT, Bioclinica, and CRF Health) offering CNS/neurological endpoints, eCOA, and wearables — broader portfolio but overlapping digital CNS assessment functionality.
- Medidata Solutions (Dassault Systèmes): Leading enterprise EDC and clinical trial platform (Rave). Although far broader, it increasingly bundles digital endpoint capture including CNS modules and is the dominant platform Cumulus must displace.
- Veeva Systems: Cloud-based life sciences platform including Veeva Vault CTMS and clinical operations — competes at the broader enterprise clinical-trial software layer where Cumulus's pharma buyers also procure.
- Signant Health: Clinical trial technology provider offering eCOA, patient-centric data capture, and CNS-focused solutions — directly competes for the same clinical-trial endpoint budgets at top pharma.
Emerging players
- Empatica: Medical-grade wearable sensors and digital biomarkers used in neurology clinical research and decentralized trials — emerging alternative for physiological data capture within CNS studies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
BrainWaveBank social profiles
Digital presenceBrainWaveBank compliance and trust
Trust signalCompliance1 record
BrainWaveBank financial estimates
Financial estimateRevenue estimate
Valuation estimate
BrainWaveBank leadership team
Management profileNumber of profiles
Profiles4 records
BrainWaveBank funding detail
Funding detailFunding overview
Funding rounds9 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BrainWaveBank M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BrainWaveBank
What does BrainWaveBank do?
BrainWaveBank develops digital tools that measure and track brain activity and cognitive performance for anyone, anytime, anywhere. The company provides multi-modal digital brain assessments combining neurophysiological data capture (including EEG) with digitized cognitive tests, enabling frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions. The technology underpins the NeuLogiq® Platform, designed in collaboration with 10 top pharmaceutical companies for use in central nervous system (CNS) clinical studies and drug development.
Is BrainWaveBank a public or private company?
BrainWaveBank is a private company. It is classified as venture growth investor backed and is currently operating.
When was BrainWaveBank founded?
BrainWaveBank was founded in 2015. It employs 1 to 10 people.
Where is BrainWaveBank based?
BrainWaveBank is headquartered in Belfast, United Kingdom, in the Europe region.
How does BrainWaveBank make money?
One revenue line is on record: clinical Trial Services.
Who are BrainWaveBank's main competitors?
Direct peers on record are Cambridge Cognition, Cogstate, VivoSense, IXICO and ActiGraph. Broad incumbents are Clario, Medidata Solutions (Dassault Systèmes), Veeva Systems and Signant Health. Empatica is listed as an emerging player.
Does BrainWaveBank have an API?
No public API is recorded for BrainWaveBank.
What industry is BrainWaveBank in?
BrainWaveBank's product category is Digital CNS Clinical Trial Technology. Its primary akta.pro industry code is HLACAOAA, Electronic Data Capture (EDC) Platforms, with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 54169 and its SIC code is 8731.